Heron Therapeutics vs Lifecore Biomedical
HRTX and LFCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HRTX and LFCR compare
Lifecore Biomedical is the larger company, worth 3.9 times as much as Heron Therapeutics ($242M against $61.9M).
Lifecore Biomedical grew revenue faster over the last twelve months (0.47% versus −4.4% for Heron Therapeutics).
Heron Therapeutics keeps more of each dollar of sales as profit, with a net margin of −14.5% compared with −30.0% at Lifecore Biomedical.
Heron Therapeutics scores higher on the StockData Score (8 against 4 for Lifecore Biomedical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HRTX | LFCR |
|---|---|---|
| Size and price | ||
| Market cap | $61.9M | $242M |
| Share price | $0.326 | $6.40 |
| Change, 1 year | −71.9% | −17.3% |
| Change, 5 years | −96.8% | −32.6% |
| Beta (5Y) | 1.80 | 1.04 |
| Employees | 128 | 382 |
| StockData Score | ||
| Total score | 8 (better) | 4 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.4× (better) | 1.9× |
| P/B | 12.6× | – |
| FCF yield | −23.2% | −5.6% (better) |
| Growth | ||
| Revenue growth (TTM) | −4.4% | 0.47% (better) |
| Revenue growth, 5Y average | 11.8% (better) | −4.2% |
| Net income growth (TTM) | – | −422% |
| EPS growth (TTM) | – | −485% |
| Profitability | ||
| Gross margin | 71.5% (better) | 31.3% |
| Operating margin | −5.7% (better) | −13.4% |
| Net margin | −14.5% (better) | −30.0% |
| FCF margin | −9.7% (better) | −10.6% |
| Return on equity | −218% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −0.8× |
| Current ratio | 2.33 | 3.84 (better) |
| Altman Z-score | −10.59 | −0.52 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −9.8% |
| Shareholder yield | 0.00% (better) | −9.8% |
| Ownership | ||
| Held by institutions | 70.4% | 67.1% |
| Held by insiders | 21.6% | 46.1% |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 22.8% | 8.4% |
Go deeper
- HRTX stock overview
- HRTX income statement
- HRTX valuation and score
- LFCR stock overview
- LFCR income statement
- LFCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.